AAAAAA

   
Results: 1-11 |
Results: 11

Authors: Dankner, WM Lindsey, JC Levin, MJ
Citation: Wm. Dankner et al., Correlates of opportunistic infections in children infected with the humanimmunodeficiency virus managed before highly active antiretroviral therapy, PEDIAT INF, 20(1), 2001, pp. 40-48

Authors: Buchacz, K Cervia, JS Lindsey, JC Hughes, MD Seage, GR Dankner, WM Oleske, JM Moye, J
Citation: K. Buchacz et al., Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children, PEDIATRICS, 108(4), 2001, pp. NIL_91-NIL_97

Authors: Gortmaker, SL Hughes, M Cervia, J Brady, M Johnson, GM Seage, GR Song, LY Dankner, WM Oleske, JM
Citation: Sl. Gortmaker et al., Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1, N ENG J MED, 345(21), 2001, pp. 1522-1528

Authors: Waecker, NJ Stefanova, R Cave, MD Davis, CE Dankner, WM
Citation: Nj. Waecker et al., Nosocomial transmission of Mycobacterium bovis bacille Calmette-Guerin to children receiving cancer therapy and to their health care providers, CLIN INF D, 30(2), 2000, pp. 356-362

Authors: Dankner, WM Davis, CE
Citation: Wm. Dankner et Ce. Davis, Mycobacterium bovis as a significant cause of tuberculosis in children residing along the United States-Mexico border in the Baja California region, PEDIATRICS, 105(6), 2000, pp. NIL_45-NIL_49

Authors: Shingadia, D Viani, RM Yogev, R Binns, H Dankner, WM Spector, SA Chadwick, EG
Citation: D. Shingadia et al., Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus, PEDIATRICS, 105(6), 2000, pp. NIL_50-NIL_54

Authors: Frenkel, LM Capparelli, EV Dankner, WM Xu, J Smith, IL Ballow, A Culnane, M Read, JS Thompson, M Mohan, KM Shaver, A Robinson, CA Stempien, MJ Burchett, SK Melvin, AJ Borkowsky, W Petru, A Kovacs, A Yogev, R Goldsmith, J McFarland, EJ Spector, SA
Citation: Lm. Frenkel et al., Oral ganciclovir in children: Pharmacokinetics, safety, tolerance, and antiviral effects, J INFEC DIS, 182(6), 2000, pp. 1616-1624

Authors: King, JC Borkowsky, W Mahidhara, N Madore, D Shapiro, ED Rutstein, RM Tan, TQ Farley, JJ Dankner, WM Nachman, S Simoes, E Flynn, PM Clemens, J Hamilton, RG
Citation: Jc. King et al., Group-specific antibody levels surrounding invasive pneumococcal illness in children infected with human immunodeficiency virus, J INFEC DIS, 181(5), 2000, pp. 1817-1821

Authors: Ngo, LY Yogev, R Dankner, WM Hughes, WT Burchett, S Xu, J Sadler, B Unadkat, JD
Citation: Ly. Ngo et al., Pharmacokinetics of azithromycin administered alone and with atovaquone inhuman immunodeficiency virus-infected children, ANTIM AG CH, 43(6), 1999, pp. 1516-1519

Authors: Viani, RM Dankner, WM Muelenaer, PA Spector, SA
Citation: Rm. Viani et al., Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube, PEDIATRICS, 104(6), 1999, pp. 1394-1396

Authors: Kline, MW Blanchard, S Fletcher, CV Shenep, JL McKinney, RE Brundage, RC Culnane, M Van Dyke, RB Dankner, WM Kovacs, A McDowell, JA Hetherington, S
Citation: Mw. Kline et al., A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection, PEDIATRICS, 103(4), 1999, pp. E471-E475
Risultati: 1-11 |